In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5155-5158

  Pfaller, Michael A ^a   Duncanson, Frederick ^b   Messer, Shawn A ^a   Moet, Gary J ^a   Jones, Ronald N ^a,c   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b EISAI INC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; E 1210; ITRACONAZOLE; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BROTH DILUTION; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS GROWTH; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMINOPYRIDINES; ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ECHINOCANDINS; ISOXAZOLES; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 80054701309     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00570-11     Document Type: Article

References (32)

1. Arendrup, M. C., et al. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080.
2. Barnes, P. D., and K. A. Marr. 2006. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect. Dis. Clin. North Am. 20:545-561. (Pubitemid 44375112)
3. Bueid, A., et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
4. Chen, A., and J. D. Sobel. 2005. Emerging azole antifungals. Expert Opin. Emerg. Drugs 10:21-33. (Pubitemid 40305255)
5. Chen, S. C., E. G. Playford, and T. C. Sorrell. 2010. Antifungal therapy in invasive fungal infections. Curr. Opin. Pharmacol. 10:522-530.
6. CLSI. 2008. M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 2nd edition. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Cuenca-Estrella, M., et al. 2007. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin. Microbiol. Infect. 13:1018-1022. (Pubitemid 47382259)
8. Espinel-Ingroff, A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48: 3251-3257.
9. EUCAST. 2010. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1, April 2010. http://www.eucast.org/clinical-breakpoints/.
10. EUCAST. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. http://www.eucast.org/documents /technical-notes/.
11. Fridkin, S. K. 2005. The changing face of fungal infections in health care settings. Clin. Infect. Dis. 41:1455-1460. (Pubitemid 41579989)
12. Howard, S. J., and M. C. Arendrup. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 49(Suppl. 1):S90-S95.
13. Howard, S. J., et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
14. Lafaurie, M., et al. 2010. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin. Microbiol. Infect. 16:1191-1196.
15. Lass-Florl, C. 2009. Azole resistance in aspergillosis: the next threat. Curr. Fungal Infect. Rep. 3:236-242.
16. Madureira, A., et al. 2007. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int. J. Antimicrob. Agents 30:551-554. (Pubitemid 350051779)
17. Messer, S. A., R. N. Jones, G. J. Moet, J. T. Kirby, and M. Castanheira. 2010. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol. 48:2984-2987.
18. Miyazaki, M., T. Horii, K. Hata, and M. Watanabe. 2010. In vitro antifungal activity of E1210: a novel antifungal with activity against clinically important yeasts and moulds, abstr. F1-840. Proc. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010.
19. Mortensen, K. L., et al. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54:4545-4549.
20. Pavie, J., et al. 2005. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J. Clin. Microbiol. 43:4902-4904. (Pubitemid 41298308)
21. Pfaller, M. A., et al. 2011. Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates. J. Clin. Microbiol. 49:1110-1112.
22. Pfaller, M. A., et al. 2009. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 47:3323-3325.
23. Pfaller, M. A., M. Castanheira, S. A. Messer, G. J. Moet, and R. N. Jones. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
24. Rodriguez-Tudela, J. L., et al. 2008. Epidemiological cutoffs and crossresistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472. (Pubitemid 351915677)
25. Spanakis, E. K., G. Aperis, and E. Mylonakis. 2006. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43:1060-1068. (Pubitemid 44631109)
26. Sun, H. Y., and N. Singh. 2010. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 35:211-218.
27. Tsukahara, K., et al. 2003. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol. Microbiol. 48:1029-1042. (Pubitemid 36628267)
28. Umemura, M., et al. 2003. GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast. J. Biol. Chem. 278:23639-23647. (Pubitemid 36830186)
29. Verweij, P. E., and M. E. Brandt. 2007. Aspergillus, Fusarium, and other opportunistic moniliaceous fungi, p. 1802-1838. In M. A. Pfaller (ed.), Manual of clinical microbiology. American Society for Microbiology, Washington, DC.
30. Verweij, P. E., S. J. Howard, W. J. Melchers, and D. W. Denning. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
31. Walsh, T. J., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360. (Pubitemid 351265310)
32. Watanabe, N., T. Horii, M. Miyazaki, and K. Hata. 2010. E1210, a new broad-spectrum antifungal, inhibits glycosylphosphatidylinositol (GPI) biosynthesis and effects Candida albicans cell characteristics, abstr. F1-841. Proc. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010.